| 引用本文: | 夏周琦,王瑞,吴纪恒,倪韶青.安罗替尼耐药性与敏感性相关研究进展[J].中国现代应用药学,2023,40(12):1652-1657. |
| XIA Zhouqi,WANG Rui,WU Jiheng,NI Shaoqing.Research Progress of anlotinib’s drug resistance and sensitivity[J].Chin J Mod Appl Pharm(中国现代应用药学),2023,40(12):1652-1657. |
|
| 本文已被：浏览 3086次 下载 906次 |
码上扫一扫！ |
|
|
| 安罗替尼耐药性与敏感性相关研究进展 |
|
夏周琦1,2,3, 王瑞2,3, 吴纪恒2,3, 倪韶青1,2,3
|
|
1.浙江大学临床药学研究中心, 杭州 310058;2.浙江大学医学院附属儿童医院临床试验机构管理办公室, 杭州 310052;3.国家儿童健康与疾病临床医学研究中心, 杭州 310052
|
|
| 摘要: |
| 安罗替尼是由中国自主研发的新型抗肿瘤小分子药物，其在多种肿瘤的临床试验中都取得了良好的疗效。在化疗过程中，耐药性和敏感性直接关系到药物对肿瘤治疗的成败。肿瘤基因的表达水平在安罗替尼的选择下产生变化，进而引起信号通路的改变使肿瘤产生耐药性。而抑制与安罗替尼耐药机制相关的基因或合用其他抗肿瘤药物可以提高肿瘤对安罗替尼的敏感性。本文总结了体外安罗替尼的耐药性和敏感性机制的相关研究，并回顾了安罗替尼联用PD-1/PD-L1抑制剂逆转安罗替尼耐药性的临床报道，以期为安罗替尼的耐药性机制研究和临床用药提供参考。 |
| 关键词: 安罗替尼 耐药性 敏感性 |
| DOI：10.13748/j.cnki.issn1007-7693.20224042 |
| 分类号:R969.3 |
| 基金项目:国家自然科学基金项目(81573516)；浙江省基础公益研究计划(LGF19H310004) |
|
| Research Progress of anlotinib’s drug resistance and sensitivity |
|
XIA Zhouqi1,2,3, WANG Rui2,3, WU Jiheng2,3, NI Shaoqing1,2,3
|
|
1.Clinical Pharmacy Research Center, Zhejiang University, Hangzhou 310058, China;2.Office of Drug Clinical Trial Institution of Children's Hospital Affiliated to Zhejiang University School of Medicine, Hangzhou 310052, China;3.National Clinical Research Center for Child Health, Hangzhou 310052, China
|
| Abstract: |
| Anlotinib is a new anti-tumor small-molecule drug independently developed by China, which has achieved good curative effect in the clinical trials of a variety of tumors. During chemotherapy, drug resistance and sensitivity are directly related to the success or failure of the tumor’s drug treatment. The expression level of the tumor genes changes under the selection of anlotinib, which then causes changes in the signaling pathways to induce the tumor’s drug resistance. While the inhibition of the genes associated with the mechanisms of anlotinib resistance or the combination of other antitumor agents can improve the tumor’s sensitivity to anlotinib. This article summarizes the relevant studies on the resistance and sensitivity mechanism of anlotinib in vitro, and reviews the clinical reports of anlotinib in combination with PD-1/PD-L1 inhibitors to reverse anlotinib resistance, in order to provide a reference for the study of anlotinib resistance mechanism and clinical application. |
| Key words: anlotinib drug resistance sensitivity |
